Why have protein biomarkers not reached the clinic?

Genome Medicine

Volumn 3, Issue 10, 2011, Pages

  Hanash, Samir M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; DNA; RNA;

CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FUNCTIONAL PROTEOMICS; GENOMICS; IMMUNOASSAY; MOLECULAR DYNAMICS; NOTE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; TRANSCRIPTOMICS;

EID: 80054943335     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm282     Document Type: Note

References (8)

1. Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila) 2011, 4:303-306. 10.1158/1940-6207.CAPR-11-0053, 21372029.
2. Fong T. NIH Proteomics Funding Fell 3 Percent in FY 2008. , http://2429-genomeweb.voxcdn.com/proteomics/nih-proteomics-funding-fell-3-percent-fy-2008
3. AAAS NIH Budgets by Institute and Funding Mechanism, FY 1998-2008. AAAS., http://www.aaas.org/spp/rd/health08c.pdf
4. Hanash S, Taguchi A. The grand challenges of cancer proteomics. Nat Rev Cancer 2010, 10:652-660. 10.1038/nrc2918, 20733593.
5. McClave CB. Biospecimens: Advancing Epidemiologic Eesearch. , http://dceg.cancer.gov/newsletter/jul09/0709_biospecimens.shtml
6. Canary Foundation. , http://www.Canaryfoundation.org
7. WIN Consortium: Worldwide Innovative Networking in Personalized Cancer Medicine. , http://www.winconsortium.org
8. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008, 100:1432-1438. 10.1093/jnci/djn326, 2567415, 18840817.